Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Receives Average Rating of “Moderate Buy” from Brokerages

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has been given an average recommendation of “Moderate Buy” by the ten ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $17.2222.

Several research analysts have recently weighed in on ADPT shares. Wall Street Zen cut shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday. JPMorgan Chase & Co. increased their price target on Adaptive Biotechnologies from $17.00 to $20.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. BTIG Research raised their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Piper Sandler upped their price objective on Adaptive Biotechnologies from $15.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday, October 15th. Finally, Morgan Stanley started coverage on Adaptive Biotechnologies in a report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 target price on the stock.

Insider Buying and Selling

In other news, CEO Chad M. Robins sold 124,998 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $18.94, for a total transaction of $2,367,462.12. Following the completion of the sale, the chief executive officer owned 2,709,241 shares of the company’s stock, valued at $51,313,024.54. The trade was a 4.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Kyle Piskel sold 162,820 shares of the company’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $19.50, for a total value of $3,174,990.00. Following the completion of the sale, the chief financial officer owned 216,637 shares of the company’s stock, valued at $4,224,421.50. This trade represents a 42.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,442,530 shares of company stock valued at $24,610,748 in the last 90 days. 6.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Ameriprise Financial Inc. raised its holdings in Adaptive Biotechnologies by 84.3% during the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after acquiring an additional 2,731,648 shares during the period. Geode Capital Management LLC raised its stake in Adaptive Biotechnologies by 15.6% during the 2nd quarter. Geode Capital Management LLC now owns 3,215,171 shares of the company’s stock valued at $37,461,000 after purchasing an additional 434,347 shares during the period. Aristotle Atlantic Partners LLC lifted its holdings in shares of Adaptive Biotechnologies by 8.6% in the third quarter. Aristotle Atlantic Partners LLC now owns 3,126,719 shares of the company’s stock worth $46,776,000 after buying an additional 247,402 shares in the last quarter. Jennison Associates LLC boosted its position in shares of Adaptive Biotechnologies by 103.9% during the fourth quarter. Jennison Associates LLC now owns 2,674,668 shares of the company’s stock worth $43,437,000 after acquiring an additional 1,363,181 shares during the last quarter. Finally, Fred Alger Management LLC increased its holdings in Adaptive Biotechnologies by 6.7% in the 3rd quarter. Fred Alger Management LLC now owns 2,514,234 shares of the company’s stock valued at $37,613,000 after acquiring an additional 158,807 shares during the last quarter. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Price Performance

ADPT stock opened at $18.50 on Wednesday. The stock has a market capitalization of $2.82 billion, a P/E ratio of -34.26 and a beta of 2.18. Adaptive Biotechnologies has a 1-year low of $6.26 and a 1-year high of $20.76. The business has a fifty day moving average price of $17.22 and a 200-day moving average price of $15.14.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. The company had revenue of $93.97 million during the quarter, compared to the consensus estimate of $58.76 million. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.Adaptive Biotechnologies’s revenue for the quarter was up 102.4% on a year-over-year basis. During the same period last year, the company earned ($0.22) EPS. As a group, analysts anticipate that Adaptive Biotechnologies will post -0.92 earnings per share for the current year.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.